The Role of Estrogen in Schizophrenia: Implications for Schizophrenia Practice Guidelines for Women

Grigoriadis, Sophie; Seeman, Mary V.

doi:10.1177/070674370204700504

Cited by 110 publications

(60 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, females may have better immediate and delayed memories than males. Female patients also may show better improvements in cognitive deficits with antipsychotic treatments potentially through normalizing estrogen's activity in the brain (Grigoriadis and Seeman, 2002;Rubin et al, 2008). However, not all studies have found sex differences in memory tasks and several have found sex differences in visuospatial and attention deficits in patients with schizophrenia (Goldstein et al, 1998;Halari et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have focused on gender differences in the cognitive deficits of schizophrenia and showed gender differences in cognitive domains in both schizophrenia and healthy populations (Goldstein et al, 2002;Halari et al, 2006;Phillips and Silverman, 1997;Ragland et al, 1999;Wisner et al, 2011). Furthermore, gender differences in schizophrenia' cognitive deficits are evident in the prodromal symptoms, acute psychotic episodes, illness course, and clinical response to antipsychotic treatment (Grigoriadis and Seeman, 2002;Hughes et al, 2003;Rubin et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gender differences in cognitive function of patients with chronic schizophrenia

Han¹,

Huang²,

Chen³

et al. 2012

Progress in Neuro-Psychopharmacology and Biological Psychiatry

122

View full text Add to dashboard Cite

Schizophrenic patients have cognitive impairments, but gender differences in these cognitive deficits have had limited study. This study assessed cognitive functioning in 471 subjects including 122 male and 78 female schizophrenic patients and 141 male and 130 female healthy controls. We found that immediate memory, language, delayed memory and total RBANS scores were significantly decreased in schizophrenia compared with healthy controls for both genders. Male patients had significant lower immediate memory, delayed memory and total RBANS scores than female patients, and healthy controls showed a similar gender difference. The RBANS showed modest correlations with PANSS scores, duration of illness and antipsychotic dose (chlorpromazine equivalents). Almost all RBANS scores in the schizophrenics and healthy controls showed significant positive correlations with education. Thus, patients of both sexes with schizophrenia experienced more deteriorated performance than healthy controls on cognitive domains of immediate memory, language and delayed memory. Furthermore, male schizophrenic patients had more serious cognitive deficits than female patients in immediate and delayed memory, but not in language, visuospatial and attention indices. AbstractSchizophrenic patients have cognitive impairments, but gender differences in these cognitive deficits have had limited study. This study assessed cognitive functioning in 471 subjects including 172 male and 78 female schizophrenic patients and 141 male and 130 female healthy controls. We found that immediate memory, language, delayed memory and total RBANS scores were significantly decreased in schizophrenia compared with healthy controls for both genders. Male patients had significant lower immediate memory, delayed memory and total RBANS scores than female patients, and healthy controls showed a similar gender difference. The RBANS showed modest correlations with PANSS scores, duration of illness and antipsychotic dose (chlorpromazine equivalents). Almost all RBANS scores in the schizophrenics and healthy controls showed significant positive correlations with education. Thus, patients of both sexes with schizophrenia experienced more deteriorated performance than healthy controls on cognitive domains of immediate memory, language and delayed memory.Furthermore, male schizophrenic patients had more serious cognitive deficits than female patients in immediate and delayed memory, but not in language, visuospatial and attention indices.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gender differences in cognitive function of patients with chronic schizophrenia

Han¹,

Huang²,

Chen³

et al. 2012

Progress in Neuro-Psychopharmacology and Biological Psychiatry

122

View full text Add to dashboard Cite

show abstract

“…In particular, results from large, control studies are needed before estrogens may be recommended as adjunct therapy in standard clinical practice for the treatment of women with schizophrenia , without proven estrogen deficiency. In contrast, other strategies should already be part of standard clinical care [77]. These include examination of the gonadal axis, with therapeutic actions, if indicated.…”

Section: Discussionmentioning

confidence: 99%

Estrogens and Gonadal Function in Schizophrenia and Related Psychoses

Riecher-Rössler¹,

Kulkarni

2010

Biological Basis of Sex Differences in Psychopharmacology

View full text Add to dashboard Cite

“…Women show differences in a number of aspects of schizophrenia compared to men, and accumulating evidence suggests that estrogen may play a protective role regarding vulnerability (for reviews see Grigoriadis and Seeman 2002;Hafner, 2003;Halbreich and Kahn, 2003). For example, a later age of onset of symptoms related to schizophrenia is observed in women (Aleman et al, 2003) and women generally respond to lower doses of medications that target D2 receptors compared to men (Seeman, 1983).…”

Section: Discussionmentioning

confidence: 99%

Effect of Menstrual Cycle Phase on Dopamine D2 Receptor Availability in Female Cynomolgus Monkeys

Czoty

Riddick

Gage

et al. 2008

Neuropsychopharmacol

View full text Add to dashboard Cite

Sex differences have been reported in a variety of affective and neurodegenerative disorders that involve dysfunctional dopamine (DA) neurotransmission. In addition, there is evidence for differences in sensitivity to the abuse-related effects of psychostimulants across the menstrual cycle which may result from effects of ovarian hormones on DA function. The goal of the present study was to extend previous work examining menstrual cycle-related changes in DA D2 receptor availability in humans to drug-naive female cynomolgus monkeys (n ¼ 7) using the selective D2-like receptor ligand [ 18 F]fluoroclebopride (FCP) and a high-resolution microPET P4 scanner. Menstrual cycle phase was characterized by daily vaginal swabs and measurements of serum progesterone levels. PET studies were conducted once during the luteal phase and once during the follicular phase. Regions of interest in the caudate nucleus, putamen, and cerebellum were defined on coregistered MRIs. Distribution volumes were calculated for FCP in each structure and the distribution volume ratio (DVR) for both brain regions relative to the cerebellum was used as a measure of D2 receptor availability. FCP DVRs were significantly higher in the luteal phase compared to the follicular phase in both the caudate nucleus (11.7% difference, p ¼ 0.02) and putamen (11.6% difference, p ¼ 0.03). These findings extend earlier work in humans and suggest that changes in DA receptor availability may be involved in the variation in symptoms of various neuropsychiatric disorders across the menstrual cycle, including differences in sensitivity to the abuse-related effects of stimulants.

show abstract

The Role of Estrogen in Schizophrenia: Implications for Schizophrenia Practice Guidelines for Women

Cited by 110 publications

References 43 publications

Gender differences in cognitive function of patients with chronic schizophrenia

Gender differences in cognitive function of patients with chronic schizophrenia

Estrogens and Gonadal Function in Schizophrenia and Related Psychoses

Effect of Menstrual Cycle Phase on Dopamine D2 Receptor Availability in Female Cynomolgus Monkeys

Contact Info

Product

Resources

About